可切除食管癌中无复发生存期作为总生存期替代终点
该研究整合10项III期随机试验的2145例R0切除患者个体数据,评估可切除食管癌围手术期治疗中无复发生存期(RFS)对总生存期(OS)的替代作用。个体水平Kendall τ为0.823,试验水平R²为0.735,均超过预设良好替代阈值,提示RFS可作为OS的替代终点。
要点
- RFS与OS在个体水平呈强替代关系(τ=0.823)。
- 试验水平替代良好(R²=0.735),支持RFS作为终点。
- RFS替代OS可缩短食管癌围手术期试验随访时间。
核心结论
- 可切除食管癌中RFS与OS在个体和试验水平均呈强替代关系。
研究设计与样本
- 整合分析10项III期随机试验的2145例R0切除患者的个体数据。
- 比较可切除食管癌和胃食管结合部癌的围手术期治疗。
主要发现
- 5年OS率为53.2%,RFS率为46.2%,中位OS为6.2年,中位RFS为3.6年。
- 个体水平Kendall τ为0.823(95%CI 0.807-0.839)。
- 新辅助化疗亚组τ为0.830(95%CI 0.800-0.861,n=586)。
- 新辅助放化疗亚组τ为0.827(95%CI 0.803-0.850,n=982)。
- 全部22项试验的试验水平R²为0.735(95%CI 0.512-0.939),替代阈值效应为0.929。
关键数值与推荐
- 预设良好替代阈值:个体水平τ≥0.8,试验水平R²≥0.65。
- 个体水平τ=0.823(95%CI 0.807-0.839)超过阈值。
- 试验水平R²=0.735(95%CI 0.512-0.939)超过阈值。
临床怎么用
- 在可切除食管癌围手术期治疗试验中,可考虑用RFS替代OS以缩短随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study evaluated recurrence-free survival (RFS) as a surrogate endpoint for overall survival (OS) in esophageal cancer. BACKGROUND: OS is regarded as the gold-standard efficacy endpoint of oncological treatments but requires long follow-up. METHODS: An integrated analysis of individual patient data (IPD) from phase III trials comparing perioperative therapies for resectable esophageal and gastroesophageal junction cancer was conducted. Surrogacy between RFS and OS was assessed at the individual level using the Kendall rank correlation coefficient (τ) and at the trial level using the coefficient of determination (R²). A τ of 0.8 and an R² of 0.65 were considered thresholds for a good surrogate. RESULTS: Twenty-two eligible trials were identified, and IPD were available from 10 randomized trials, including 2,145 patients who underwent R0 resection. The 5-year OS and RFS rates were 53.2% and 46.2%, with median OS of 6.2 and RFS of 3.6 years. For individual-level surrogacy, Kendall's τ was 0.823 (95% confidence interval [CI]: 0.807-0.839). Subgroup analysis by treatment modality revealed τ values of 0.830 (95% CI: 0.800-0.861) for neoadjuvant chemotherapy (NAC; n=586), and 0.827 (95% CI: 0.803-0.850) for neoadjuvant chemoradiotherapy (NACRT; n=982). Trial-level surrogacy analysis across all 22 trials demonstrated an R2 of 0.735 (95% CI: 0.512-0.939). The surrogate threshold effect was 0.929. CONCLUSIONS: This study demonstrated strong individual- and trial-level surrogacy between RFS and OS in resectable esophageal cancer across all perioperative treatments. These findings may accelerate perioperative treatment development by shortening follow-up in esophageal cancer trials.
引用
- Okui J, Matsuda S, Nagashima K, et al. Recurrence-free Survival as a Surrogate Endpoint for Overall Survival in Resectable Esophageal Cancer: Integrated Analysis of Individual Patient Data From Phase III Trials. Ann Surg. 2025. PMID: 40853558. doi:10.1097/SLA.0000000000006919
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。